Objective:

To present data on XEN-45 gel stent implantation for the treatment of refractory secondary glaucoma (SG) in a Chinese patient population, highlighting its significance in improving patient outcomes.

Key Findings:

• XEN-45 gel stents effectively manage various forms of refractory secondary glaucoma, with a reported success rate of X%.
• The ab externo implantation techniques resulted in minimal intraocular manipulation and rapid recovery, with a complication rate of Y%.
• The study included diverse SG cases, enhancing the understanding of XEN-45's applicability across different patient demographics.

Interpretation:

The XEN-45 gel stent is a promising minimally invasive option for patients with refractory secondary glaucoma, potentially reducing complications associated with traditional surgeries, such as hypotony and bleb leaks.

Limitations:

• The study's sample size and follow-up duration may limit the generalizability of the findings, particularly in diverse populations.
• Comparative analyses with other surgical techniques were not included, which may affect the robustness of the conclusions drawn.

Conclusion:

XEN-45 gel stent implantation is a viable treatment for refractory secondary glaucoma, offering a safer alternative to traditional surgical methods, with implications for improving patient management strategies.